These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 31396956

  • 1. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
    Arriga R, Caratelli S, Lanzilli G, Ottaviani A, Cenciarelli C, Sconocchia T, Spagnoli GC, Iezzi G, Roselli M, Lauro D, Coppola A, Dotti G, Ferrone S, Sconocchia G.
    Int J Cancer; 2020 May 01; 146(9):2531-2538. PubMed ID: 31396956
    [Abstract] [Full Text] [Related]

  • 2. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
    Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, Cenciarelli C, Venditti A, Del Principe MI, Lauro D, Landoni E, Du H, Savoldo B, Ferrone S, Dotti G, Sconocchia G.
    Int J Cancer; 2020 Jan 01; 146(1):236-247. PubMed ID: 31479522
    [Abstract] [Full Text] [Related]

  • 3. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F.
    J Clin Oncol; 2009 Mar 01; 27(7):1122-9. PubMed ID: 19164213
    [Abstract] [Full Text] [Related]

  • 4. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
    Trotta AM, Ottaiano A, Romano C, Nasti G, Nappi A, De Divitiis C, Napolitano M, Zanotta S, Casaretti R, D'Alterio C, Avallone A, Califano D, Iaffaioli RV, Scala S.
    Cancer Immunol Res; 2016 Apr 01; 4(4):366-74. PubMed ID: 26817995
    [Abstract] [Full Text] [Related]

  • 5. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY.
    Int J Mol Sci; 2021 Jul 14; 22(14):. PubMed ID: 34299137
    [Abstract] [Full Text] [Related]

  • 6. Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex.
    Zhu Q, Zhang R, Gu X, Zhao Z, Gao Q, Chen M, Wu Q, Xie T, Sui X.
    Theranostics; 2024 Jul 14; 14(14):5443-5460. PubMed ID: 39310106
    [Abstract] [Full Text] [Related]

  • 7. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation.
    Ohishi T, Kato Y, Kaneko MK, Ohba SI, Inoue H, Harakawa A, Kawada M.
    Int J Mol Sci; 2020 Aug 21; 21(17):. PubMed ID: 32839411
    [Abstract] [Full Text] [Related]

  • 8. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.
    Rodríguez J, Zarate R, Bandres E, Boni V, Hernández A, Sola JJ, Honorato B, Bitarte N, García-Foncillas J.
    Eur J Cancer; 2012 Aug 21; 48(12):1774-80. PubMed ID: 22305465
    [Abstract] [Full Text] [Related]

  • 9. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
    Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F.
    Int J Cancer; 2014 May 01; 134(9):2146-55. PubMed ID: 24136682
    [Abstract] [Full Text] [Related]

  • 10. Targeting CD137 enhances the efficacy of cetuximab.
    Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, Mueller A, Sagiv-Barfi I, Marabelle A, Lira R, Troutner E, Richards L, Rajapaska A, Hebb J, Chester C, Waller E, Ostashko A, Weng WK, Chen L, Czerwinski D, Fu YX, Sunwoo J, Levy R.
    J Clin Invest; 2014 Jun 01; 124(6):2668-82. PubMed ID: 24837434
    [Abstract] [Full Text] [Related]

  • 11. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 12. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H, Liu Y, Wu K, Luo H, Cui L.
    Cell Commun Signal; 2020 Jul 23; 18(1):115. PubMed ID: 32703218
    [Abstract] [Full Text] [Related]

  • 13. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
    Fujii R, Schlom J, Hodge JW.
    J Neurosurg; 2018 May 23; 128(5):1419-1427. PubMed ID: 28753113
    [Abstract] [Full Text] [Related]

  • 14. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, Okabayashi K, Tsuruta M, Hasegawa H, Kitagawa Y.
    Oncol Rep; 2014 May 23; 31(5):2115-22. PubMed ID: 24626880
    [Abstract] [Full Text] [Related]

  • 15. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
    Zhang H, Yuan L, Liu L, Yan C, Cheng J, Fu Q, Tong Z, Jiang W, Zheng Y, Zhao P, Zhang G, Fang W.
    BMC Cancer; 2020 May 13; 20(1):416. PubMed ID: 32404198
    [Abstract] [Full Text] [Related]

  • 16. Stress-induced Rab11a-exosomes induce amphiregulin-mediated cetuximab resistance in colorectal cancer.
    Mason JD, Marks E, Fan SJ, McCormick K, Wilson C, Harris AL, Hamdy FC, Cunningham C, Goberdhan DCI.
    J Extracell Vesicles; 2024 Jun 13; 13(6):e12465. PubMed ID: 38887984
    [Abstract] [Full Text] [Related]

  • 17. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T.
    Theranostics; 2020 Jun 13; 10(11):5107-5119. PubMed ID: 32308771
    [Abstract] [Full Text] [Related]

  • 18. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
    Schlaeth M, Berger S, Derer S, Klausz K, Lohse S, Dechant M, Lazar GA, Schneider-Merck T, Peipp M, Valerius T.
    Cancer Sci; 2010 May 13; 101(5):1080-8. PubMed ID: 20331636
    [Abstract] [Full Text] [Related]

  • 19. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.
    Borrero-Palacios A, Cebrián A, Gómez Del Pulgar MT, García-Carbonero R, Garcia-Alfonso P, Aranda E, Elez E, López-López R, Cervantes A, Valladares M, Nadal C, Viéitez JM, Guillén-Ponce C, Rodríguez J, Hernández I, García JL, Vega-Bravo R, Puime-Otin A, Martínez-Useros J, Del Puerto-Nevado L, Rincón R, Rodríguez-Remírez M, Rojo F, García-Foncillas J.
    Sci Rep; 2019 Feb 22; 9(1):2589. PubMed ID: 30796344
    [Abstract] [Full Text] [Related]

  • 20. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
    Lee HW, Son E, Lee K, Lee Y, Kim Y, Lee JC, Lim Y, Hur M, Kim D, Nam DH.
    Int J Mol Sci; 2019 Nov 24; 20(23):. PubMed ID: 31771279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.